Improving family medicine in China and battling COVID-19 with smart systems
Format
Dr Wu Hao has devoted his career to improving community health and integrating technology, data systems and efficient management to serve a growing population
In the 11 years that Dr Wu Hao has headed the Fangzhuang Community Health Service Centre in the Fengtai district of Beijing, its outpatient volume has soared from fewer than 110 000 to 440 000 today.
The centre, which has just 25 general practitioners and a team of nurses, has transformed the way community health is practiced in the capital region, especially in the management of chronic diseases like hypertension and diabetes.
See eTable 1 in Supplement 2 for definitions of each analysis population. Among those receiving aluminum hydroxide (alum) for the first dose, 5 participants received WIV04 (n = 2) and HB02 (n = 3) vaccines for the second dose and were not included in the safety analysis population of the alum-only group (13 458 – 5 = 13 453), but were included in the WIV04 and HB02 groups, respectively. Three participants who received WIV04 for the first dose and HB02 for the second dose and 3 participants who received HB02 for the first dose and WIV04 for the second dose were included in both groups (WIV04: 13 459 + 2 + 3 = 13 464; HB02: 13 465 + 3 + 3 = 13 471). To measure neutralization antibody levels, the first 900 participants from each study site were selected. There were 9 participants in the WIV04 group, 7 in the HB02 group, and 8 in alum-only group who had adverse events or serious adverse events (SAEs) after the first dose and did not receive the secon
/PRNewswire/ HeMo Bioengineering Ltd ("HeMo"), a Singapore-based medical device company with a focus on treating stroke patients, is pleased to announce.
eggeeggjiew / iStock
Although nonhospitalized COVID-19 patients are at low risk for delayed complications, they visit their general practitioner or clinic more often than their uninfected peers in the 6 months after testing positive, finds a population-based study published yesterday in
The Lancet Infectious Diseases.
The study, led by researchers from the University of Southern Denmark, involved comparing 8,983 living, nonhospitalized COVID-19 patients with 80,894 Danish residents who tested negative for the virus from Feb 27 to May 31, 2020. Both groups were followed for 2 weeks to 6 months after testing.
Both groups were at similar risk for being diagnosed as having a new health condition at a hospital (risk difference [RD], 26.3% vs 28.8%), but COVID-19 patients were more likely to be diagnosed as having breathing problems (RD, 1.2% vs 0.7%; adjusted RR [aRR], 2.00) or venous thromboembolism (blood clots in the veins) (RD, 0.2% vs 0.1%; aRR, 1.77).
Antengene Announces Selinexor Added to Multiple Treatment Regimens in 2021 CSCO Guidelines
News provided by
Share this article
Share this article
SHANGHAI and HONG KONG, May 5, 2021 /PRNewswire/ Antengene Corporation Limited ( Antengene , SEHK: 6996.HK), a leading innovative biopharmaceutical company dedicated to discovering, developing and commercializing global first-in-class and/or best-in-class therapeutics in hematology and oncology, today announced that the Chinese Society of Clinical Oncology (CSCO), the most prominent organization in oncology in China,
added multiple selinexor regimens to its 2021 Diagnosis and Treatment Guidelines (CSCO Guidelines) for treatment of multiple myeloma and lymphoma. Three selinexor regimens recommended by the Guideline for the Diagnosis and Treatment of myeloma include: (i) selinexor plus dexamethasone; and (ii) selinexor plus dexamethasone plus bortezomib; and (iii) selinexor plus dexamethasone plus pomalidomide for the treatment of re